Sponsors (7)
The bill reduces consumer-directed drug advertising—potentially lowering misleading promotion and prescribing pressure and creating regulatory clarity—while risking reduced patient awareness of treatments, wider information disparities for those with limited clinician access, and possible cost-shifting by manufacturers.
Patients with chronic conditions and hospitals/health systems will face less promotional pressure to choose newer, expensive branded drugs, which could reduce spending on medications and influence toward lower-cost options.
Patients (particularly those with chronic conditions) will be exposed to fewer commercial drug promotions, reducing the chance of seeing potentially misleading marketing and lowering risks of inappropriate demand or prescribing driven by ads.
Drug sponsors, hospitals, and health systems will have a uniform rule for covered drugs with predictable compliance requirements and an FDA enforcement start date 30 days after enactment, reducing regulatory uncertainty.
Patients (including seniors and retirees) may have reduced awareness of newly approved or important treatment options marketed directly to consumers, potentially delaying access to beneficial therapies.
Low-income individuals and residents of rural communities may become more reliant on clinicians for drug information as manufacturers cut consumer-facing information, worsening access disparities for people with limited provider access.
Patients (including Medicare and Medicaid beneficiaries) and payers could face higher costs if drug companies reallocate marketing budgets to other channels or raise drug prices to offset lost consumer advertising.
Based on analysis of 2 sections of legislative text.
Introduced June 12, 2025 by Bernard Sanders · Last progress June 12, 2025
Prohibits direct-to-consumer advertising for certain drugs by adding a new prohibition to the Federal Food, Drug, and Cosmetic Act. The prohibition covers drugs approved or licensed under federal drug/biologics statutes that meet a specified regulatory condition and whose application or license holder has run direct-to-consumer promotions in the most recent 30 days. "Direct-to-consumer advertising" is defined broadly to include television, radio, print, digital platforms, and social media. The rule takes effect 30 days after enactment and applies to covered drugs regardless of when they were approved or licensed.